BioTuesdays

Author - Stephen Kilmer

MindMed Logo
Markets

Cantor starts MindMed at OW; PT $3

Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...

August 10, 2022
scPharmaceuticals Logo
Markets

Maxim starts scPharmaceuticals at buy; PT $10

Maxim Group initiated coverage of scPharmaceuticals (NASDQ:SCPH) with a “buy” rating and price target of $10. The stock closed at $4.89 on Aug. 2. scPharmaceuticals is a late-stage pre-commercial company developing...

August 2, 2022
Keros Therapeutics Logo
Markets

BTIG starts Keros at buy; PT $80

BTIG launched coverage of Keros Therapeutics (NASDAQ:KROS) with a “buy” rating and $80 price target. The stock closed at $28.53 on July 25. Analyst Julian Harrison writes that following Acceleron’s impressive foray into...

July 26, 2022
Liquidia Logo
Markets

Ladenburg starts Liquidia at buy; PT $15

Ladenburg Thalmann initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $15 price target. The stock closed at $5.03 on July 21. Liquidia is a commercial-stage biotechnology company currently focused on...

July 22, 2022
Markets

SVB Securities starts Morphic Holding at OW; PT $45

SVB Securities launched coverage of Morphic Holding (NASDAQ:MORF) with an “outperform” rating and $45 price target. The stock closed at $24.99 on July 19. Morphic is a clinical-stage biotechnology company developing...

July 20, 2022
Clene Logo
Markets

HCW starts Clene at buy; PT $16

H.C.Wainwright initiated coverage of Clene (NASDAQ:CLNN) with a “buy” rating and price target of $16. The stock closed at $4.50 on July 15. Clene is focused on the development of novel clean-surfaced nanotechnologies...

July 18, 2022
Oyster Point Pharma Logo
Markets

HCW starts Oyster Point Pharma at buy; PT $20

H.C. Wainwright launched coverage of Oyster Point Pharma (NASDAQ:OYST) with a “buy” rating and $20 price target. The stock closed at $4.43 on July 15. Oyster Point Pharma is a commercial stage biopharmaceutical company...

July 18, 2022